Skip to main content
. 2021 Jan 21;12(5):659–666. doi: 10.1111/1759-7714.13823

FIGURE 3.

FIGURE 3

Tumor‐educated platelet (TEP) SNORD55 as a biomarker for non‐small cell lung cancer (NSCLC) diagnosis and early diagnosis. (a) The receiver operating characteristic (ROC) curve analysis of SNORD55 for NSCLC. (b) The ROC curve analysis of NSCLC for early‐stage lung cancer. (c) The levels of carcinoembryonic antigen (CEA) were increased in early‐stage NSCLC patients (n = 86) compared with healthy controls (n = 140). (d–f) The ROC curve analysis of CEA (AUC = 0.726), SNORD55 (AUC = 0.731), and the combination (AUC = 0.828) for early‐stage NSCLC. AUC, area under the curve; CEA, carcinoembryonic antigen; ES‐NSCLC, early‐stage NSCLC patients; HD, healthy donors. ****p < 0.0001